LA JOLLA, Calif., March 25, 2013 /PRNewswire-USNewswire/ -- The California Institute for Biomedical Research (Calibr) and JDRF announced a partnership today to apply Calibr's drug discovery expertise to type 1 diabetes research projects in collaboration with academic investigators from JDRF's network. Termed the Translational Academic Research Partnership, the jointly funded Calibr-JDRF program will establish collaborative projects focused on promising type 1 diabetes therapeutic targets and the discovery of early drug leads for validation and follow-on development. The initial collaborative projects will be seeded by leading academic investigators working in the area of beta cell biology. Calibr's Matt Tremblay explained the rationale, "The idea is to team up Calibr's chemical and high-throughput screening technologies with the beta cell experts from JDRF's network to validate targets and create new drug discovery programs in areas of novel biology." The first year of the program will focus on promoting survival of pancreatic beta cells as an approach to restoring blood glucose control in type 1 diabetic patients.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.
As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness.For more information, please visit www.jdrf.org. About Calibr: The California Institute for Biomedical Research (Calibr) is an independent, not-for-profit organization established to accelerate the translation of basic biomedical research to innovative new medicines. The Institute partners with academic scientists around the world to translate research discoveries and new technologies into innovative new therapies for unmet medical needs. Calibr is led by Peter G. Schultz, Ph.D., a world-renowned chemist, biotechnology entrepreneur and Professor of Chemistry at The Scripps Research Institute in San Diego, CA. Located in San Diego, Calibr is housed in newly built labs located near The Scripps Research Institute, The Salk Institute for Biological Studies, the University of California, San Diego and Sanford-Burnham Medical Research Institute. Contact:The California Institute for Biomedical Research (Calibr) Amit BhatiaVP of Finance & OperationsT: +1-858-242-1000F: +1-858-242-1001 firstname.lastname@example.org SOURCE The California Institute for Biomedical Research